Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
Company facts
| Company | Abeona Therapeutics Inc. |
|---|---|
| Symbol | ABEO |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $313.37M (Massive market data, 2026-09-10) |
| Employees | 226 |
| Country | United States |
| Website | https://www.abeonatherapeutics.com |
Trading — Abeona Therapeutics Inc.
| Last price | $5.41 |
|---|---|
| Change | -1.19% |
| Previous close | $5.48 |
| Day range | $5.40 – $5.66 |
| 50-day average | $6.40 |
| 200-day average | $5.52 |
| Average volume | 1,340,111 |
Price basis: yfinance_daily_bar_close · 2026-09-11T21:07:44.986755+00:00
Valuation and financial health
| Earnings per share | $-1.10 |
|---|---|
| Price / book | 2.45 |
| Enterprise value / EBITDA | -3.37 |
| Enterprise value / sales | 10.66 |
| Debt / equity | 0.12 |
| Current ratio | 6.63 |
| Dividend yield | 0.00% |
| Free cash flow | -$81.53M |
| Cash ratio | 2.27 |
| Enterprise value | $272.13M |
Reported 2026-09-10
Earnings
| Report date | 2026-11-11 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | 2026-09-30 |
| EPS estimate | -0.17 |
Source: optionsai supplemental public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABEO are on the IntelTrends dashboard.